Overview of systematic reviews/Meta-analysis of Xingnaojing Injection in treatment of intracerebral hemorrhage.
10.19540/j.cnki.cjcmm.20210622.501
- Author:
Min WANG
1
;
Min JIA
2
;
Wan-Qing DU
3
;
Xin-Yang ZHANG
4
;
Wei-Wei JIAO
2
;
Qian CHEN
4
;
Lin LEI
4
;
Jia-Yu DUAN
4
;
Chen-Guang TONG
2
;
Yun-Ling ZHANG
2
;
Xing LIAO
5
Author Information
1. Graduate School, Beijing University of Chinese Medicine Beijing 100029, China Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
3. Graduate School, Beijing University of Chinese Medicine Beijing 100029, China Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
4. Graduate School, Beijing University of Chinese Medicine Beijing 100029, China.
5. Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Review
- Keywords:
Xingnaojing Injection(XNJ);
a measurement tool to assess systematic evaluation 2(AMSTAR 2);
efficacy;
grades of recommendation,assessment,development and evaluation(GRADE);
intracerebral hemorrhage;
overview of systematic review
- MeSH:
Cerebral Hemorrhage/drug therapy*;
Drugs, Chinese Herbal;
Humans;
Meta-Analysis as Topic;
Reproducibility of Results;
Systematic Reviews as Topic;
United States
- From:
China Journal of Chinese Materia Medica
2021;46(18):4633-4643
- CountryChina
- Language:Chinese
-
Abstract:
To overview of systematic reviews/Meta-analysis of Xingnaojing Injection(XNJ) in the treatment of intracerebral hemorrhage(ICH). The systematic reviews concerning XNJ in the treatment of ICH were retrieved from four Chinese databases, four English databases, Chinese Clinical Trial Registry and ClinicalTrail.gov, with the retrieval time set from their inception to September 2020. Following the independent screening and data extraction by two researchers, a measurement tool to assess systematic evaluation 2(AMSTAR 2) and grades of recommendation, assessment, development and evaluation(GRADE) system were used to evaluate the metho-dological, reporting and evidence qualities of the 10 included systematic reviews. The results showed that XNJ was superior to the wes-tern medicine or conventional treatment in improving the effective rate and National Institutes of Health stroke scale(NIHSS) score, Barthel index(BI), and Glasgow coma scale(GCS) score and Chinese stroke scale(CSS) score, and reducing the mortality and cerebral hematoma volume, without inducing obvious adverse reactions. In general, the methodological, reporting and evidence qualities of the 10 included systematic reviews were poor. The AMSTAR 2 scores showed that key items No. 2 and No. 16 failed to meet the stan-dard, resulting in poor methodological quality. There was only one outcome indicator graded by GRADE as intermediate quality, 43% indicators as low quality, 42% indicators as extremely low quality, and none as high quality. These available evidences have suggested that the methodological, reporting and evidence qualities of the systematic evaluation concerning XNJ for the treatment of ICH need to be improved. Most evidences support that XNJ was better than the western medicine or conventional treatment in the treatment of ICH, but the methodological quality and the reliability of outcome indicators in relevant systematic review were low. More high-quality studies are still required for further verification.
